Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part B - Behavioral results

Table 10 Regression Analyses of Changes in Autism Severity vs. Urinary Metal Excretion (after 9^th dose of DMSA in Phase 1) and Changes in Glutathione (Dglut).

	Adjusted R²	P-value	Equation	Most significant variables
Change in PDD-BI (n = 32)	0.59	0.002	7-rnd group (17.9 -2.62 Pb9 +0.230 Sn9 +102Tl9 -135Sb9 - 1.01 As9 -0.0695 Dglut) 1-rnd group (-32.7 -0.564 Pb9 +0.0755Sn9 +17.4 Tl9 +13.8 Sb9 -0.476 As9 +0.045 Dglut)	7-rnd group: Dglut*, As9, Sb9, Tl9, Pb9*
				1-round group: No significant terms
Change in ATEC (n = 32)	0.25	0.02	7-rnd group (1.93 -7.82 Hg9 -0.352 As9) 1-rnd group (-4.91 -0.672 Hg9 -0.260 As9)	7-rnd group: Hg9*, As9
				1-rnd group: No significant terms
Change in SAS (n = 29)	0.22	n.s.	(not listed since not significant)
Change in ADOS (comm.. + social) (n = 32)	0.18	n.s.	(not listed since not significant)

Both treatment groups analyzed together, with individual coefficients for each group. Only the PDD-BI and ATEC yielded significant results, and only the 7-round group variables had significant coefficients. In the regression equation, the suffixes for the metals refer to the value at Baseline (B) and after the 9^th dose of DMSA (9). Note that initial glutathione did not contribute to any of the final equations.